Advance Online
Older man with beard carrying a woman with curly hair, both smiling, on his back in the woods.
Advance Online

FDA Approves First Oral Treatment for All Psoriasis Severities

Apremilast has been approved for mild-to-moderate psoriasis severity.

On December 21, 2021, the U.S. Food and Drug Administration (FDA) extended the approval of Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, now including those individuals who have mild or moderate plaque psoriasis severity.1 

Otezla® is an oral medication which works by inhibiting phosphodiesterase 4 specific for cyclic adenosine monophosphate (cAMP). With this expanded indication, Otezla® is now the first (and only) oral treatment approved in adult patients across all psoriasis severities.1 

This expanded approval is based on findings from the Phase 3 ADVANCE trial, which found that that 5-times as many adults with mild-to-moderate plaque psoriasis achieved a Static Physician's Global Assessment (sPGA) response (defined as a sPGA score of clear [0] or almost clear [1] with at least a 2-point reduction from baseline) at week 16 compared to placebo. In addition, improvements were seen in Whole Body Itch Numeric Rating Scale response and Scalp Physicians Global Assessment.1

Previously, Otezla® was approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, and for oral ulcers associated with Behcet’s Disease. 

Psoriasis Affects More Than Your Skin

Explore how psoriatic disease affects other areas of your body, and why it's important to treat even mild psoriasis.

Read more

Reference

1: https://www.prnewswire.com/news-releases/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level-301448542.html

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.